Multicenter, Retrospective GUIDANCE001 Study Comparing Transarterial Chemoembolization with or Without Tyrosine Kinase and Immune Checkpoint Inhibitors As Conversion Therapy to Treat Unresectable Hepatocellular Carcinoma: Survival Benefit in Intermediate or Advanced, but Not Early, Stages.

Da-Long Yang, Lin Ye, Fan-Jian Zeng, Jie Liu, Hong-Bing Yao, Jun-Liang Nong, Shao-Ping Liu,Ning Peng, Wen-Feng Li,Pei-Sheng Wu, Chuang Qin, Ze Su, Jun-Jie Ou,Xiao-Feng Dong, Yi-He Yan, Teng-Meng Zhong, Xian-Shuang Mao,Ming-Song Wu, Yao-Zhi Chen, Guo-Dong Wang, Mian-Jing Li, Xue-Yao Wang,Fu-Quan Yang, Yong-Rong Liang, Shu-Chang Chen, Yong-Yu Yang,Kang Chen, Fu-Xin Li, Yong-Cheng Lai, Qing-Qing Pang,Xiu-Mei Liang, Xue-Mei You,Bang-De Xiang, Ya-Qun Yu,Liang Ma,Jian-Hong Zhong

HEPATOLOGY（2025）

Cited 0|Views2

Key words

conversion therapy,HCC,immune checkpoint inhibitors,transarterial chemoembolization,tyrosine kinase inhibitors,unresectable

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined